

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)



(10) International Publication Number
WO 2021/142275 A1

(51) International Patent Classification:

C12N 15/00 (2006.01) A61K 47/00 (2006.01)
C12N 15/09 (2006.01) A61K 47/50 (2017.01)
C12N 15/63 (2006.01)

(21) International Application Number:

PCT/US2021/012719

(22) International Filing Date:

08 January 2021 (08.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/959,788	10 January 2020 (10.01.2020)	US
62/965,740	24 January 2020 (24.01.2020)	US
62/968,761	31 January 2020 (31.01.2020)	US
63/055,513	23 July 2020 (23.07.2020)	US
63/061,833	06 August 2020 (06.08.2020)	US
63/132,929	31 December 2020 (31.12.2020)	US

(71) Applicant: **DYNE THERAPEUTICS, INC.** [US/US];
830 Winter Street, Waltham, MA 02451 (US).

(72) Inventors: **SUBRAMANIAN, Romesh R.**; 830 Winter Street, Waltham, MA 02451 (US). **QATANANI, Mohammed T.**; 830 Winter Street, Waltham, MA 02451 (US). **WEEDEN, Timothy**; 830 Winter Street, Waltham, MA 02451 (US). **DESJARDINS, Cody A.**; 830 Winter Street, Waltham, MA 02451 (US). **QUINN, Brendan**; 830 Winter Street, Waltham, MA 02451 (US). **RHODES, Jason P.**; 830 Winter Street, Waltham, MA 02451 (US).

(74) Agent: **GE, Zhiyun** et al.; Wolf, Greenfield & Sacks, P.C.,
600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY




FIG. 7

(57) Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*